David Hutton

home

authors

david-hutton

Nicox SA announced that the last patients completed their final (3-month) visit in the Mont Blanc Phase 3 clinical trial of NCX 470 0.1% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

A total of 691 patients were enrolled in the trial. NCX 470, Nicox’s lead clinical product candidate, is a novel, potentially best-in-class, nitric oxide (NO)-donating prostaglandin analogue eye drop.

“We are pleased to have reached this milestone in the Mont Blanc Phase 3 clinical trial, and I would particularly like to thank our clinical sites and the Nicox development team for their incredible efforts in continuing to drive this trial to completion in the face of the COVID-19 pandemic situation.” Doug Hubatsch, EVP, Chief Scientific Officer of Nicox, said in a news release. “NCX 470 has the potential to be a best-in-class glaucoma treatment, and we look forward to sharing the top line results in early November.”

Mont Blanc is a multi-regional, double-masked, 3-month, parallel group trial evaluating the efficacy and safety of NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution, 0.005%. Latanoprost is the most widely prescribed first-line therapy for open-angle glaucoma or ocular hypertension. The primary efficacy evaluation in Mont Blanc is based on time-matched IOP at 8 AM and 4 PM at Week 2, Week 6 and Month 3.

The second Phase 3 trial on NCX 470, Denali, is being jointly conducted and equally financed with Nicox SA’s Chinese partner, Ocumension Therapeutics. Top line results are currently expected after 2024.

Articles

According to Nicox SA, the patients made their final 3-month visit last week. Top line results of the trial are expected in November.

Mont Blanc: Final visit completed in Phase 3 trial of NCX 470 for the treatment of glaucoma

Videos

At the 2022 American Academy of Ophthalmology meeting, Dr Philip Dockery, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

Younger patients often require repeat corneal crosslinking, study finds

Dr Mark H. Blecher dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL

David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.

Author | David Hutton

Articles

Younger patients often require repeat corneal crosslinking, study finds

Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL

Utilising AAO cornea preferred practice patterns for corneal oedema, opacifications, ectasia and bacterial keratits

Mont Blanc: Final visit completed in Phase 3 trial of NCX 470 for the treatment of glaucoma